Evidence map›Paper›PMID 33361337›Full record

Trial reportJournal for immunotherapy of cancer2020

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in

Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Rosalie Stephens, Inge Marie Svane and 9 more

Erratum issuedOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 112 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 7 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 7 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  9. Trial
  10. Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  17. Review
  18. Article
  19. Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 8 countries.

Pier Francesco FerrucciCancer Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy pier.ferrucci@ieo.it.ORCID 0000-0001-6255-5851
Anna Maria Di GiacomoCenter for Immuno-Oncology, University Hospital of Siena; University of Siena, Siena, Italy.
Michele Del VecchioUnit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Victoria AtkinsonUniversity of Queensland, and Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Woolloongabba, Queensland, Australia.
Henrik SchmidtDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Jacob SchachterDivision of Oncology, Sheba Medical Centre, Tel HaShomer Hospital, Tel Aviv, Israel.
Paola QueiroloDivisione di Oncologia Medica del Melanoma, Sarcoma e Tumori Rari, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-9917-6633
Georgina V LongMelanoma Institute Australia, The University of Sydney, and Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID 0000-0001-8894-3545
Rosalie StephensMedical Oncology, Auckland City Hospital, Auckland, New Zealand.
Inge Marie SvaneDepartment of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Michal LotemSharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Mahmoud Abu-AmnaRambam Health Care, Haifa, Israel.
Eduard GasalGlobal Drug Development, Oncology, Novartis, East Hanover, New Jersey, USA.
Razi GhoriDepartment of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.
Scott J DiedeDepartment of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.ORCID 0000-0001-5422-549X
Elizabeth S CroydonDepartment of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA.
Antoni RibasDepartment of Medicine, University of California Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.
Paolo Antonio AsciertoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.ORCID 0000-0002-8322-475X
KEYNOTE-022 international team
Merck & Co., Inc., Rahway, NJ, USA (United States) · USMelanoma Institute Australia · AUAarhus University Hospital · DKAuckland City Hospital · NZCenter for Global Development · USEuropean Institute of Oncology · ITHadassah Medical Center · ILHerlev Hospital · DKOspedale Policlinico San Martino · ITRambam Health Care Campus · ILSheba Medical Center · ILThe University of Queensland · AUThe University of Sydney · AUUniversity of California, Los Angeles · USUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.

methodsThe double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated

resultsBetween November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy. With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83). With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively. Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06). With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%). Grade 3-5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet.

conclusionIn

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodFemaleHumansImidazolesMaleMelanomaOximesPyridonesPyrimidinonesSurvival AnalysisAntibodies, Monoclonal, HumanizeddabrafenibImidazolesOximespembrolizumabPyridonesPyrimidinonestrametinibcombinationdrug therapyimmunotherapymelanomaprogrammed cell death 1 receptor

Identifiers

PMID33361337
PMCPMC7768966
OpenAlexW3114356388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.